Non-integrative Sendai Virus Induction of Neural Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing neural stem cells using viral or plasmid vectors face challenges such as genetic mutations, difficulty in obtaining cells, contamination risks, and ethical concerns, particularly in treating Parkinson's disease with dopaminergic precursors.
Innovation Solution
A method involving non-integrative Sendai virus vectors to induce neural stem cells from peripheral blood mononuclear cells, which are then differentiated into dopaminergic precursors and transplanted into the striatum to treat Parkinson's disease, using a process that includes expansion, transduction, and high-temperature inactivation of the virus to prevent genetic integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If retroviral vectors carrying Sox2 are used to transduce human fibroblasts, then neural stem cell clones appear after 6-10 days, but the retroviral gene sequence integrates into the host cell's gene sequence causing mutations
Solution Approach 1:
The patent extracts the harmful integration function from the viral vector system. By using Sendai virus vectors that deliver genes through non-integrative mechanisms (RNA transfection), the gene delivery function is separated from the harmful integration function, achieving fast induction without genetic mutation risk
Solution Approach 2:
The patent introduces Sendai virus as an intermediary carrier that facilitates gene delivery without integrating into host DNA. The Sendai virus acts as a temporary vector that delivers transcription factors and then degrades, avoiding the harmful integration step while maintaining efficient gene expression
2Object-affected harmful factors
If non-integrative plasmid vectors are used to electrotransduce cells, then neural stem cells can be produced without integration, but the process requires complex electrotransduction and long culture periods
Solution Approach 1:
The patent replaces the mechanical electrotransduction process with a biological viral transduction process. Sendai virus vectors naturally infect cells and deliver genes through endocytosis, eliminating the need for complex electrotransduction equipment and procedures while achieving non-integrative gene delivery
Solution Approach 2:
The patent changes the delivery mechanism parameter from physical (electrotransduction) to biological (viral transduction). This parameter change simplifies the process, reduces culture time, and maintains non-integrative gene delivery, addressing both the harmful integration and time loss issues
3Ease of manufacture
If fibroblasts are obtained from human tissue, then neural stem cells can be induced, but the process is traumatic and requires long in vitro culture
Solution Approach 1:
The patent inverts the traditional approach by using peripheral blood mononuclear cells (PBMCs) as the starting material instead of fibroblasts. PBMCs can be obtained minimally invasively from peripheral blood, eliminating the need for traumatic tissue biopsy and long fibroblast culture periods
Solution Approach 2:
The patent performs preliminary cell isolation from peripheral blood, which is a minimally invasive procedure that can be done at the time of donation. This preliminary action avoids the need for subsequent traumatic tissue harvesting and extended culture periods required for fibroblast derivation
4Productivity
If integrative viral vectors are used, then efficient gene delivery is achieved, but genetic mutations occur in host cells
Solution Approach 1:
The patent extracts the integration function from the viral vector system. Sendai virus vectors deliver genes through non-integrative RNA transfection mechanisms, separating efficient gene delivery from the harmful integration function, thereby maintaining productivity while eliminating genetic mutations
Solution Approach 2:
The patent uses Sendai virus vectors that are designed to be temporary and non-integrating. These vectors deliver genes efficiently but then degrade without integrating into host DNA, acting as a disposable delivery system that maintains efficiency without the long-term harmful effects of integration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively differentiates neural stem cells into dopaminergic neurons, reduces tumorigenesis risk, and improves behavioral outcomes in animal models of Parkinson's disease, offering a safe and efficient cell transplantation treatment.
Implementation Method 1
transducing the expanded PBMNCs with a Sendai viral vector carrying OCT4, SOX2, c-MYC and KLF-4 genes
Implementation Method 2
transferring the neural stem cell clones for neural stem cell expansion in which the neural stem cells are subjected to a high-temperature culture to obtain Sendai virus-inactivated neural stem cells
Implementation Method 3
differentiating the neural stem cells into dopaminergic precursors
Data Source
AI summary
A method of treating neurodegenerative diseases or disorders, especially Parkinson's disease and a method of inducing neural stem cells from peripheral blood mononuclear cells. The induced neural stem cells can express neural stem cell-related genes and differentiate into neurons, astrocytes and oligodendrocytes. The dopaminergic precursors derived from the induced neural stem cells are transplanted into the striatum of the PD mouse models without any sign of tumorigenesis, thereby improving the behaviors of the PD mouse models and slowing down the progression of Parkinson's disease.